{"schema_version":"secwatch.filing_event.v1","accession":"0000885590-21-000050","form_type":"8-K","ticker":"BHC","cik":"0000885590","company_name":"Bausch Health Companies Inc.","filed_at":"2021-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.998510+00:00","generated_at":"2026-06-28T19:26:40.427637+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bausch Health names Tom Vadaketh as future CFO, Sam Eldessouky to move to Bausch + Lomb","bullets":["Sam Eldessouky will become CFO of Bausch + Lomb upon closing of its IPO.","Tom Vadaketh joins from eResearch Technology and will succeed Eldessouky as Bausch Health CFO at IPO close.","Vadaketh receives annual base salary of $600,000, target bonus of 60% of base, sign-on cash of $500,000, and equity grant of $3 million.","Employment agreement has initial three-year term with automatic one-year renewals."],"urls":{"canonical":"https://secwatch.observer/filing/0000885590-21-000050","json":"https://secwatch.observer/filing/0000885590-21-000050.json","markdown":"https://secwatch.observer/filing/0000885590-21-000050.md","text":"https://secwatch.observer/filing/0000885590-21-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885590/000088559021000050/0000885590-21-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885590/000088559021000050/bhc-20211020.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T19:26:40.427637+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a9f37a489d","claim":"Sam Eldessouky departed as Chief Financial Officer at Bausch Health Companies Inc..","evidence_excerpt":"Sam Eldessouky, the current Chief Financial Officer of Bausch Health, will become Chief Financial Officer of Bausch + Lomb, effective as of the closing of the initial public offering of Bausch + Lomb","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/885590/000088559021000050/0000885590-21-000050-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will become"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"efc5530f27","claim":"Tom Vadaketh was appointed as Chief Financial Officer at Bausch Health Companies Inc..","evidence_excerpt":"On January 3, 2022, Tom Vadaketh will join Bausch Health from eResearch Technology Inc., and will serve as the Chief Financial Officer of the Company’s pharmaceutical business and, in connection with Mr. Eldessouky’s appointment as Chief Financial Officer of Bausch + Lomb at the time of the IPO, Mr. Vadaketh will be appointed as Chief Financial Officer of Bausch Health, effective as of the IPO Closing Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/885590/000088559021000050/0000885590-21-000050-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}